孟鲁司特治疗儿童咳嗽变异性哮喘的临床观察

Clinical therapeutic effect of Montelukast on cough variant asthma in children

目的:观察孟鲁司特治疗儿童咳嗽变异性哮喘的临床疗效和安全性。方法:将65例咳嗽变异性哮喘患儿随机分为治疗组32例和对照组33例,分别给予酮替酚和孟鲁司特口服,连用6个月。结果:治疗组达到临床缓解所需时间及随访半年的复发率均明显低于对照组(P<0.01和P<0.05),而治疗3个月及6个月时呼气峰流速(PEF)预计值>90%的比率则高于对照组(P<0.05),且未见明显不良反应。结论:孟鲁司特治疗儿童咳嗽变异性哮喘安全有效,可改善肺功能,降低复发率。

Objective： To investigate the clinical effect of montelukast in treating and preventing children＇s cough variant asthma（CVA） and its safety. Methods： 65 children with CVA were randomly divided into treatment group（n=32） and control group （n =33）, received orally treatment of Montelukast and Ketotifen for 6 months respectively. Results： There were significant differences in time reaching clinically relieve and rate of recurrence that follow-up for 6 months, the treatment group was lower than control group （P〈0.01 and P〈0.05）. The rate of peak expiratory flow rates （PEF） 〉90% in treatment group was higher than those of control group 3, 6 months after treatment（P〈0.05）. The treatment group had few side reaction occurred. Conclusion： Montelukast is safe and effective in treatment of children＇s CVA, it can improve lung function and reduce rate of recurrence.